Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence
- 26 February 2008
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 68 (7) , 698-714
Abstract
BACKGROUND Following androgen ablation therapy, the majority of prostate cancer patients develop treatment resistance with a median time of 18–24 months to disease progression. METHODS To identify molecular targets that promote prostate cancer cell survival and contribute to androgen independence, we evaluated changes in LNCaP cell gene expression during 12 months of androgen deprivation. At time points reflecting critical growth and phenotypic changes, we performed Affymetrix expression array analysis to examine the effects of androgen deprivation during the acute response, during the period of apparent quiescence, and following the emergence of a highly proliferative, androgen-independent prostate cancer cell phenotype (LNCaP-AI). RESULTS We discovered alterations in gene expression for molecules associated with promoting prostate cancer cell growth and survival, and regulating cell cycle progression and apoptosis. Additionally, expression of AR co-regulators, adrenal androgen metabolizing enzymes, and markers of neuroendocrine disease were significantly altered. CONCLUSIONS These findings contribute greatly to our understanding of androgen-independent prostate cancer. The value of this longitudinal approach lies in the ability to examine gene expression changes throughout the adaptive response to androgen deprivation; it provides a more dynamic illustration of genes which contribute to disease progression in addition to specific genes which constitute an androgen-independent phenotype. Prostate 68: 698–714, 2008.Keywords
Funding Information
- Department of Defense Predoctoral Grant (PC050142)
- Department of Pathology
- NIH (5P30CA047904-18, RO1CA095239)
This publication has 49 references indexed in Scilit:
- Androgen Deprivation Increases p300 Expression in Prostate Cancer CellsCancer Research, 2007
- Endothelin Receptor A Blockade Enhances Taxane Effects in Prostate CancerNeoplasia, 2006
- Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor KinaseIn vivoClinical Cancer Research, 2006
- Role of the SurvivinGene in PathophysiologyThe American Journal of Pathology, 2006
- In Vitro Transcription Amplification and Labeling Methods Contribute to the Variability of Gene Expression Profiling with DNA MicroarraysThe Journal of Molecular Diagnostics, 2006
- Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation TherapyEuropean Urology, 2004
- Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinomaThe Prostate, 2003
- Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble ratCarcinogenesis, 2001
- Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptorsNature, 1996
- Studies on the human prostatic cancer cell line LNCaPThe Journal of Steroid Biochemistry and Molecular Biology, 1994